JAMA Studies Provide More Ammunition For Trial Disclosure Reformers
This article was originally published in The Pink Sheet Daily
Executive Summary
JAMA studies focus on the high number of terminated and unreported trials, plus discrepancies in publicly reported trial results. Publication comes as the Institute of Medicine consults stakeholders about trial data sharing and ahead of new reporting laws in Europe.